Orthocell Appoints Surgical Specialties As Exclusive Distributor
Published: Oct 11, 2017
- Surgical Specialties appointed as exclusive distributor in Australia and New Zealand of Orthocell’s world leading tendon regeneration (Ortho-ATI®) and cartilage regeneration therapy (Ortho-ACI®)
- Surgical Specialties has established relationships with leading orthopaedic surgeons and sports physicians and has a team of over 70 people, with sales offices throughout Australia and New Zealand
- Exclusive distributor to expand the network of referring doctors and physicians
PERTH, Australia--(BUSINESS WIRE)--Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has appointed Surgical Specialties Pty Ltd (Surgical Specialties) as its exclusive distributor in Australia and New Zealand for its world leading cell therapies for tendon regeneration (Ortho-ATI®) and cartilage regeneration (Ortho-ACI®).
“Surgical Specialties is a leading distributor of innovative medical devices and one of the few local companies with its own national sales force and marketing teams,” said Managing Director of Orthocell, Paul Anderson. “Surgical Specialties is the ideal partner with established relationships with leading orthopaedic surgeons and sports physicians, a successful track record and a highly skilled and dedicated national sales force,” he added.
Surgical Specialties will take over distribution responsibilities for Orthocell’s cell therapies including targeted promotion activities and initiating sales, as well as assisting with expanding the network of referring doctors and physicians. The exclusive distribution agreement has a term of five years and the arrangement will allow Orthocell to maintain its focus on the development of its novel regenerative medicine products and driving national and international regulatory approvals for its technologies.
“We are very excited to be involved with Orthocell. Orthocell has the only cell therapy intervention listed on the Australian Register of Therapeutic Goods (ARTG) for the repair of damaged or degenerate cartilage in the knee or ankle joint, and an innovative market leading approach for the repair of degenerate tendons. Both products are based on ground-breaking technology and addresses a significant clinical need, particularly in the orthopaedic and sports physician market,” said CEO of Surgical Specialties, Phil Nicholl.
About Surgical Specialties Pty Ltd:
Established in 2006, Surgical Specialties now has a team of over 70 people, with sales offices throughout Australia and New Zealand. Surgical Specialties is an independent distributor of innovative medical devices to the Australian and New Zealand medical community. The business focuses on the following surgical areas: Arthroplasty, Extremities, Specialty Trauma, Orthobiologics, Critical Care and Operating Room Products.